Tag: Bureau of Competition

By a 3-1-1 vote, the Federal Trade Commission today closed its investigation into Genzyme Corporation's (Genzyme) 2001 acquisition of Novazyme Pharmaceuticals, Inc. (Novazyme). At the time of its...

The Federal Trade Commission has published a notice describing the types of agreements that brand-name pharmaceutical and generic drug manufacturers must file with the FTC and the U.S. Department of...

The Federal Trade Commission has issued a unanimous policy statement on the use of monetary equitable remedies such as disgorgement and restitution in competition cases – specifically, those involving...

Presenting keynote remarks at an annual conference on "Current Topics in Merger and Antitrust Enforcement" in Washington, DC, today Federal Trade Commission Competition Director Joe Simons announced...

The Federal Trade Commission today released the materials relating to the workshop on Health Care Competition Law and Policy, held on September 9-10, 2002. The workshop focused on the implications of...

Joe Simons, Director of the Federal Trade Commission's Bureau of Competition, today announced the formation of the Merger Litigation Task Force, which will be headed by Michael Cowie, an Assistant...

The Federal Trade Commission today announced a proposed consent order with Bayer AG (Bayer) and Aventis S.A. (Aventis) that will allow Bayer's proposed purchase of Aventis's subsidiary Aventis...